Home Microbiome The Stanford Microbiome Therapies Initiative (MITI) Launches to Develop New Therapies Based...

The Stanford Microbiome Therapies Initiative (MITI) Launches to Develop New Therapies Based on the Microbiome

155
0
The Stanford Microbiome Therapies Initiative (MITI) Launches to Develop New Therapies Based on the Microbiome

Thanks to generous donations ($17m) from Marc and Lynne Benioff (Salesforce) and Mark and Debra Leslie (Veritas), Stanford is now launching an initiative to harness the communities of microbes inhabiting the human body—known as the microbiome—to develop new therapies for debilitating diseases. Known as the Stanford Microbiome Therapies Initiative (MITI), it is a joint initiative with Stanford ChEM-H and the Department of Bioengineering.

Ambitious Goals

The Stanford team seeks to develop and transform the microbiome to create new therapies that will be utilized in clinical trials. Microbiome science holds considerable promise for the advancement of new therapies to treat various diseases.

Lead Research/Director

Michael Fischbach, Associate Professor of Bioengineering will lead MITI

Carolyn Bertozzi, Professor of Chemistry, Baker Family Co-Director of Stanford ChEM-H

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.